High insulin levels in newly diagnosed breast cancer patients reflect underlying insulin resistance and are associated with components of the insulin resistance syndrome
- 306 Downloads
Background High insulin levels have been associated with poor outcomes in breast cancer. Our goal was to investigate whether hyperinsulinemia was associated with insulin resistance in a cohort of newly diagnosed locoregional breast cancer patients and to examine associations of hyperinsulinemia with the broader insulin resistance syndrome (IRS). Methods Five hundred and four women with T1-3, N0-1, M0 breast cancer provided fasting blood that was analyzed for glucose, insulin and lipids. They underwent anthropomorphic measurements and provided information on diet, exercise and sleep. Relationships of insulin with three validated indices of insulin resistance and with attributes of the IRS were examined. Results High insulin levels were strongly correlated with insulin resistance calculated using the three indices of insulin resistance/sensitivity (Spearman r = 0.83–0.98). Hyperinsulinemia was also associated with other components of the IRS (obesity, high waist–hip ratio, lipid profile). Conclusions High insulin levels in women with locoregional breast cancer reflect the presence of insulin resistance and are associated with other components of the IRS. These observations have implications for the development of therapies that target hyperinsulinemia in early stage breast cancer and for the long-term management of breast cancer survivors.
KeywordsBreast cancer Insulin Insulin resistance Obesity
This research was funded by the Canadian Breast Cancer Research Alliance and the Medical Research Council of Canada (currently the Canadian Institutes of Health Research).
- 1.Seidell JC (2005) Epidemiology of obesity. Semin Vasc Med 5:3–14Google Scholar
- 3.Goodwin PJ (2006) Energy balance and cancer prognosis: breast cancer. In: McTiernan A (ed) Cancer prevention and management through exercise and weight control. CRC Press, Boca Raton, FL, pp 405–435Google Scholar
- 6.Pollak MN, Chapman JW, Shepherd L et al (2006) Insulin resistance, estimated by serum C-peptide level, is associated with reduced event-free survival for postmenopausal women in NCIC CTG MA.14 adjuvant breast cancer trial. In: Grunberg SM (ed) Proceedings of the 42nd American society of clinical oncology annual meeting, Georgia, June 2006. Supplement to Journal of Clinical Oncology, vol 24. American Society of Clinical Oncology, Alexandria, VA, p 9sGoogle Scholar
- 18.American Diabetes Association (1998) Consensus Development Conference on Insulin Resistance. Diabetes Care 21:310–314Google Scholar
- 23.Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) (2001) Expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA 285:2486–2497Google Scholar
- 27.National Institutes of Health (1982) Manual of laboratory operations, lipid research clinics program: I. Lipid and lipoprotein analysis. Bethesda, MDGoogle Scholar
- 47.Goodwin PJ, Pritchard KI, Fantus IG, Ennis M, Clemons M, Graham M (2006) Metformin lowers fasting insulin levels in hyperinsulinemia early stage breast cancer patients––results of a phase II study. Breast Cancer Res Treat 100(Suppl 1):A2085Google Scholar
- 50.Chapman J-A, Meng D, Shepherd L et al (2008) Competing causes of death from a randomized trial of extended adjuvant endocrine therapy for breast cancer. J Natl Cancer Inst 200:252–260Google Scholar